Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Anacor Pharma Appoints Paul Berns As President And CEO - Quick Facts

RELATED NEWS
Trade ANAC now with 

Anacor Pharmaceuticals Inc. (ANAC: Quote) announced that its board has appointed Paul Berns, Anacor's Chairman of the Board of Directors, to assume the role of President and Chief Executive Officer, effective immediately. Berns succeeds David Perry who has served as Anacor's President and Chief Executive Officer since 2002.

Berns has over 20 years of industry experience as an executive in biotechnology and pharmaceutical companies.

Anacor said that Berns has served as a member of the company's board since 2012. From March 2006 to August 2012, Berns served as President and Chief Executive Officer, and member of the Board of Directors, of Allos Therapeutics, Inc., which was acquired by Spectrum Pharmaceuticals, Inc. in August 2012.

From June 2002 to July 2005, Berns was president, Chief Executive Officer and a director of Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation in 2005. From 2001 to 2002, Berns served as Vice President and General Manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories. From 2000 to 2001, he served as Vice President, Marketing of BASF Pharmaceuticals/Knoll and, from 1990 to 2000, Berns held various positions, including senior management roles, at Bristol-Myers Squibb Company. Berns has been a director of Jazz Pharmaceuticals, PLC since 2010 and of XenoPort, Inc. since 2005.

Register
To receive FREE breaking news email alerts for Anacor Pharmaceuticals, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Yukiya Amano, Director General of the International Atomic Energy Agency (IAEA), said Monday that nuclear programs of the Democratic People's Republic of Korea (DPRK) and Iran remain matters of serious concern. The head of the United Nations nuclear watchdog made the remarks at the opening of the... Stocks largely turned in a lackluster performance during trading on Monday, as traders looked ahead to the Federal Reserve's monetary policy announcement later this week. Technology stocks saw significant weakness, however, resulting in a sharp drop by the tech-heavy Nasdaq. While most Americans support President Barack Obama's decision to take action against the terrorist group ISIS, the results of a new NBC News/Wall Street Journal/Annenberg poll found that the vast majority lack confidence that the U.S. will achieve its goals.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.